Skip to main content

ABI Shares Slide 5.5 Percent After Bank Downgrades Stock; Lackluster Organic Revenue Growth Cited

NEW YORK, May 24 (GenomeWeb News) - Shares in Applied Biosystems were down 5.48 percent, or $1.24, at $21.37 in late-afternoon trading today after an investment bank downgraded the stock.


UBS downgraded the stock to 'Reduce' from 'Neutral' this morning. The bank said that "given lackluster organic revenue growth, increasing competition, and our view that transforming M&A choices may be limited, we do not believe ABI shares should trade at a premium to the group multiple at this time," according to a Reuters report.


UBS stressed that ABI "remains an important brand name in the life sciences sector."

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.